Table 4 Antidiabetic and concomitant pharmacotherapy with or without observed initiation of BOT
Treatment | Total Population | BOT(observed) | BOT(not observed) | p-value |
|---|---|---|---|---|
(N = 31,008) | (N = 6,705) | (N = 24,303) | ||
n (%) | n (%) | n (%) | ||
Monotherapy | ||||
Metformin | 19,866 (64.1) | 4,235 (63.2) | 15,651 (64.4) | 0.06 |
Sulfonylurea | 4,532 (14.6) | 1,012 (15.1) | 3,520 (14.5) | 0.21 |
Glucosidase inhibitors | 241 (0.8) | 56 (0.8) | 185 (0.8) | 0.53 |
Glitazones | 158 (0.5) | 33 (0.5) | 125 (0.5) | 0.92 |
Glinides | 1397 (4.5) | 361 (5.4) | 1,036 (4.3) | <0.001 |
DPP-4 inhibitor | 4,141 (13.4) | 1,023 (15.3) | 3,118 (12.8) | <0.0001 |
No. of OADs | <0.0001 | |||
1 OAD | 26,861 (86.6) | 5,564 (83.0) | 21,297 (87.6) | |
2 OADs | 3,818 (12.3) | 1,049 (15.6) | 2,769 (11.4) | |
≥ 3 OADs | 329 (1.1) | 92 (1.4) | 237 (1.0) | |
Concomitant medication | <0.0001 | |||
no drug | 16,959 (54.7) | 3,409 (50.8) | 13,550 (55.8) | |
1 drug | 5,762 (18.6) | 1,150 (17.2) | 4,612 (19.0) | |
2 drugs | 2,697 (8.7) | 566 (8.4) | 2,131 (8.8) | |
≥ 3 drugs | 5,590 (18.0) | 1,580 (23.6) | 4,010 (16.5) |